for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guardant Health Inc

GH.O

Latest Trade

83.22USD

Change

0.55(+0.67%)

Volume

1,137,516

Today's Range

81.85

 - 

84.52

52 Week Range

55.90

 - 

112.22

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
82.67
Open
83.46
Volume
1,137,516
3M AVG Volume
23.84
Today's High
84.52
Today's Low
81.85
52 Week High
112.22
52 Week Low
55.90
Shares Out (MIL)
98.26
Market Cap (MIL)
8,177.12
Forward P/E
-59.95
Dividend (Yield %)
--

Next Event

Guardant Health Inc at William Blair Growth Stock Conference

Latest Developments

More

Guardant Health Announces Proposed Public Offering Of Common Stock

Guardant Health Posts Quarterly Loss Per Share Of $0.27

Guardant Health Announces Collaboration With Amgen To Develop A Global Liquid Biopsy Companion Diagnostic For Amg 510 Kras G12c Inhibitor

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guardant Health Inc

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Industry

Biotechnology & Drugs

Contact Info

505 Penobscot Dr

REDWOOD CITY, CA

94063-4737

United States

+1.650.2907575

http://www.guardanthealth.com

Executive Leadership

AmirAli Talasaz

Chairman of the Board, President, Chief Operating Officer

Helmy A. Eltoukhy

Chief Executive Officer, Director

Derek Bertocci

Chief Financial Officer

Kumud Kalia

Chief Information Officer

Michael J. Wiley

Chief Legal Officer

Key Stats

1.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2018

-2.800

2019

-0.840

2020(E)

-1.388
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.34
Price To Book (MRQ)
10.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-12.01
Return on Equity (TTM)
-10.26

Latest News

Latest News

BRIEF-Guardant Health Announces Pricing Of Upsized Public Offering

* GUARDANT HEALTH ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING

BRIEF-Guardant Health Announces Proposed Public Offering Of Common Stock

* GUARDANT HEALTH ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Guardant Health Posts Quarterly Loss Per Share Of $0.27

* GUARDANT HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2020 OUTLOOK

SoftBank's Vision Fund to borrow $4 billion against stakes in Uber and two others: FT

SoftBank's Vision Fund is looking to borrow $4 billion against its stakes in Uber Technologies Inc, soon-to-go-public Slack Technologies Inc, and blood-testing company Guardant Health Inc, the Financial Times reported, citing people directly involved in the deal.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up